A group of Japanese researchers announced on Friday that transplanted pluripotent stem cells (iPS) will cause transplantation in the brain of a patient suffering from Parkinson's disease, the first trial of this kind in the world.
Team of the University of Kyoto injected 2.4 million iPS cells that can be performed to create any type of cell, in the left part of the brain in three hours in October.
A man about 50 years old has been well spent on treatment and remains under surveillance for another two years, the Kyoto University said in a statement.
If there are problems in the next six months, researchers will implant 2.4 million additional cells, this time in the right part of the brain.
These iPS healthy-donor cells should develop into dopamine-producing neurons, a neurotransmitter involved in engine monitoring.
In July, the Kyoto University announced that it would do a Clinical trial with seven between 50 and 69 years.
The Parkinson's disease is characterized by neuronal degeneration, Symptoms that are gradually worsened, such as trembling, stiffness of the muscles and loss of physical fitness.
Here you can read: Parkinson's could originate from an attachment
This affects more than ten million people in the world, according to American Parkinson's Foundation Disease. V Colombia has more than 220,000 people with this disease, according to the Columbian Association of Neuroscience. Currently available therapy "improves symptoms without slowing the progression of the disease," explains the foundations.
New inquiries focus on redirecting evil. Pred A clinical trial in humans has been conducted with monkeys with human stem cells which has enabled the improvement of the mobility of primates affected by a series of Parkinson's disease, according to a study published at the end of August 2017 in a scientific journal Nature.
For two years, the survival rate of transplanted cells was accurately controlled by injection in the brain of the primates and no tumor was detected.
Indurane pluripotent stem cells (iPS) are adult cells that are reduced to an almost embryonic state to produce four genes (usually inactive in adults). This genetic manipulation returns the ability to make any cell according to the place where the body is transplanted.
The use of iPS cells does not present important ethical problems, unlike stem cells derived from human embryos.